Dr. Raman Puri
Evidence for Intensive LDL-C-lowering for the Acute Coronary Syndrome
- During the first-month post-ACS, the risk of cardiovascular (CV) events is the highest.
- Trials of high-intensity statins have shown a reduction in MACE in the acute, early and late phases of ACS.
- The level of LDL-C is directly linked to the amount of plaque stabilization and the number of CV events.
- High-intensity statins with ezetimibe should be started at emergency triage.
- An extended lipid profile should be measured in emergency triage and repeated at weeks 2 and 4.
- Identify the ASCVD risk category and LDL-C target per the LAI recommendation.
- Plan a combination of lipid-lowering medications to achieve the LDL-C target.
- All ASCVD risk factors should be controlled, and lifestyle interventions implemented.
Dr. Raman Puri
Dr. Raman Puri is an experienced Interventional Cardiologist with 39+ years in the field. He is a Fellow in Cardiology, National Cardiovascular Centre, Osaka, Japan, and also a Clinical Fellow in Interventional Cardiology Hospital Charles, Nicolas, France. He has written several publications in reputed international as well as national medical journals.
More FAQs by Dr. Raman Puri
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article